Hypertension and its treatment influence changes in fasting nonesterified fatty acid concentrations: A link between the sympathetic nervous system and the metabolic syndrome?

Metabolism: Clinical and Experimental

Volumn 49, Issue 1, 2000, Pages 81-87

  Maison, Patrick ^a,b   Byrne, Christopher D ^a,b   Hales, C Nicholas ^a,b   Wareham, Nicholas J ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FATTY ACID;

ADRENERGIC SYSTEM; ADULT; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIURETIC THERAPY; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; FEMALE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OBESITY; PRIORITY JOURNAL; SYNDROME X; SYSTOLIC BLOOD PRESSURE;

EID: 0033958348     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(00)90788-1     Document Type: Article

References (46)

1. Reaven GM: The role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
2. Haffner SM, Valdez RA, Hazuda HP, et al: Prospective analysis of insulin-resistance syndrome (syndrome X). Diabetes 41:715-722, 1992
3. Taskinen MR: Strategies for the diagnosis of metabolic syndrome. Curr Opin Lipidol 4:434-443, 1993
4. Haffner SM: Insulin and blood pressure: Fact or fantasy? J Clin Endocrinol Metab 76:541-543, 1993
5. Ferrannini E, Buzzigoli G, Bonadonna R, et al: Insulin resistance in essential hypertension. N Engl J Med 317:350-357, 1987
6. Falkner B, Hulman D, Tannebaum J, et al: Insulin resistance and blood pressure in young black men. Hypertension 16:706-711, 1990
7. Weichenhain B, van Kooten HJ, Standl E: Hypertension and insulin resistance. Drugs 46:183-188, 1993 (suppl 2)
8. Julius S, Gudbrandsson T, Jamerson K, et al: The hemodynamic link between insulin resistance and hypertension. J Hypertens 9:983-986, 1991
9. Baron AD, Brechtel-Hook G, Johnson A, et al: Skeletal muscle blood flow. A possible link between insulin resistance and blood pressure. Hypertension 21:129-135, 1993
10. Mbanya JCN, Thomas TH, Wilkinson R, et al: Hypertension and hyperinsulinemia: A relation in diabetes but not in essential hypertension. Lancet 1:733-739, 1988
11. Muller DC, Elahi D, Pratley RE, et al: An epidemiological test of the hyperinsulinemia-hypertension hypothesis. J Clin Endocrinol Metab 76:544-548, 1993
12. Egan BM: Neurohumoral, hemodynamic, and microvascular changes as mechanisms of insulin resistance in hypertension: A provocative but partial picture. Int J Obes 15:30-36, 1991
13. Hennes MMI, O'Shaughnessy IMO, Kelly TM, et al: Insulinresistant lipolysis in abdominally obese hypertensive individuals. Role of the renin-angiotensin system. Hypertension 28:120-126, 1996
14. Egan BM, Hennes MM, Stepniakowski KT, et al: Obesity hypertension is related more to insulin's fatty acid than glucose action. Hypertension 27:723-728, 1996
15. Randle PJ, Garland PB, Hales CN, et al: The glucose-fatty acid cycle, its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785-789, 1963
16. Charles MA, Eschwege E, Thibult N, et al: The role of non-esterified fatty acids in the deterioration of glucose tolerance in caucasian subjects: Results of the Paris Prospective Study. Diabetologia 40:1101-1106, 1997
17. Paolisso G, Tataranni PA, Foley JE, et al: A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 38:1213-1217, 1995
18. Byrne CD, Wareham NJ, Day NE, et al: Decreased nonesterified fatty acid suppression and features of the insulin resistance syndrome occur in a subgroup of individuals with normal glucose tolerance. Diabetologia 38:1358-1366, 1995
19. Byrne CD, Wareham NJ, Day NE, et al: Hypertriglyceridaemia in subjects with normal and abnormal glucose tolerance: Relative contributions of insulin secretion, insulin resistance and suppression of plasma non-esterified fatty acids. Diabetologia 37:889-896, 1994
20. Tuck ML: The sympathetic nervous system in essential hypertension. Am J Cardiol 112:877-886, 1986
21. Christin L, Ravussin E, Bogardus C, et al: The effect of propranolol on free fatty acid mobilization and resting metabolic rate. Metabolism 38:439-444, 1989
22. Stepniakowski KT, Goodfriend TL, Egan BM: Fatty acids enhance vascular α-adrenergic sensitivity. Hypertension 25:II774-II778, 1995
23. Tuck ML: Obesity, the sympathetic nervous system, and essential hypertension. Hypertension 19:167-177, 1992 (suppl)
24. Williams DRR, Wareham NJ, Brown DC, et al: Undiagnosed glucose intolerance in the community: The Isle of Ely Diabetes Project. Diabet Med 12:30-35, 1995
25. Wareham NJ, Byrne CD, Williams DRR, et al: Fasting proinsulin concentrations predict the development of type 2 diabetes. Diabetes Care 22:262-270, 1999
26. Kunst A, Draeger B, Ziegenhorn J: UV-methods with hexokinase and glucose-6-phosphate dehydrogenase, in Bergmeyer HU (ed): Methods of Enzymatic Analysis, vol 4. Weinheim, Germany, Verlag Chemie, 1983, pp 163-172
27. Sobey WJ, Beer SF, Carrington CA, et al: Sensitive and specific two site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins. Biochem J 260:535-541, 1989
28. Alpha B, Cox L, Crowther N, et al: Sensitive amplified immunoenzymometric assays (IEMA) for human insulin and intact proinsulin. Eur J Clin Chem Biochem 30:27-32, 1992
29. Shimizu S: Enzymatic determination of serum-free fatty acids: A colorimetric method. Anal Biochem 107:193-198, 1980
30. Sheu WH, Jeng CY, Shieh SM, et al: Suppression of non esterified fatty acid concentrations by insulin in patients with hypertension. Chin Med J 56:367-372, 1995
31. Stepniakowski KT, Goodfriend TL, Egan BM: Fatty acids enhance vascular α-adrenergic sensitivity. Hypertension 25:II774-II778, 1995
32. Day JL, Metcalfe J, Simpson CN: Adrenergic mechanisms in control of plasma lipid concentrations. BMJ 284: 1145-1148, 1982
33. Lithell H, Pollare T, Vessby B: Metabolic effects of pindolol and propranolol in double-blind cross-over study in essential hypertension. Blood Press 1:92-101, 1992
34. Rebuffe-Scrive M: Neuroregulation of adipose tissue: Molecular and hormonal mechanisms, Int J Obes 15:83-86, 1991
35. Beauville M, Harant I, Crampes F, et al: Effect of long-term rhGH administration in GH-deficient adults on fat cell epinephrine response. Am J Physiol 263:E467-E472, 1992
36. Bianda TL, Hussain MA, Keller A, et al: Insulin-like growth factor-I in man enhances lipid mobilization and oxidation induced by growth hormone pulse. Diabetologia 39:961-969, 1996
37. Palatini P, Casiglia E, Pauletto P, et al: Relationship of tachycardia with high blood pressure and metabolic abnormalities. Hypertension 30:1267-1273, 1997
38. Liao D, Sloan RP, Cascio WE, et al: Multiple metabolic syndrome is associated with lower heart rate variability. Diabetes Care 21:2116-2122, 1998
39. Facchini FS, Stoohs RA, Reaven GM: Enhanced sympathetic nervous system activity. The linchpin between insulin resistance, hyperinsulinemia and heart rate. Am J Hypertens 9:1013-1017, 1996
40. Sowers JK, Whitfield LA, Catania RA, et al: Role of the sympathetic nervous system in blood pressure maintenance in obesity. J Clin Endocrinol Metab 54:1181-1187, 1982
41. Hoffstedt J, Shimizu M, Sjostedt S, et al: Determination of beta 3-adrenoceptor mediated lipolysis in human fat cells. Obes Res 3:447-457, 1995
42. Klein S, Edward JP, Holland OB, et al: Effect of short- and long-term β-adrenergic blockade on lipolysis during fasting in humans. Am J Physiol 257:E65-E73, 1989
43. Lipworth BJ: Clinical pharmacology of beta 3-adrenoceptors. Br J Clin Pharmacol 42:291-300, 1996
44. Pollare T, Lithell H, Selinus I, et al: Sensitivity to insulin during treatment with atenolol and metoprolol: A randomized, double blind study of effects on carbohydrate and lipoprotein metabolism in hyperten-sive patients. BMJ 298:1152-1157, 1989
45. Lake CR, Ziegler MG, Coleman MD, et al: Hydrochlorothiazide-induced sympathetic hyperactivity in hypertensive patients. Clin Pharmacol Ther 26:428-432, 1979
46. Leren P: Comparison of effects on lipid metabolism of antihypertensive drugs with alpha- and beta-adrenergic antagonist properties. Am J Med 82:31-35, 1987